Hearty results: MenaQ7 K2 study confirms vascular health benefits for men and women


01 Mar 2018 --- A new one-year clinical trial has just been completed showing that a daily nutritional dose of MenaQ7 vitamin K2 as MK-7 improved vascular health in both male and female healthy participants. This study adds support to the substantial body of evidence confirming Vitamin K2 is a cardiovascular-support nutrient.

Completed by the expert researchers at VitaK, the placebo-controlled randomized clinical trial demonstrated the benefits of 180 µg/day of MK-7 (as MenaQ7 from NattoPharma) on vascular health and body composition in 243 healthy subjects (77 men and 166 women) with a poor vitamin K status, as measured by dp-ucMGP (inactive Matrix Gla Protein, a marker for cardiovascular health). 

According to the researchers, “We enrolled participants with poor K status; however, in West most are K deficient as measured by activation of K-dependent proteins.” 

In the total group MK-7 decreased dp-ucMGP significantly compared to placebo after 1 year. 

The researchers conclude that 1-year supplementation of MK-7 tended to improve vascular health in men and women with a poor vitamin K status. The beneficial effect was more pronounced in post-menopausal women and in subjects with a high Stiffness Index. 

“This study is extremely important because this is the second trial to demonstrate benefits of MenaQ7 for cardiovascular health. But where participants in our first study were healthy postmenopausal women, this is the first trial where the effects were examined in both men and women,” says Hogne Vik, NattoPharma Chief Medical Officer. “In this study, the participants taking MenaQ7 maintained arterial flexibility and the stiffness did not increase, whereas placebo group became stiffer and less flexible.

“These results mirror what we have seen in epidemiological studies, where populations who consume a lot of dietary vitamin K2 have healthier hearts and more flexible arteries,” Vik continues.

NutritionInsight has previously reported on the significant role of vitamin K2 as a cardiovascular-condition targeter and for its artery improving characteristics


To contact our editorial team please email us at editorial@cnsmedia.com

NattoPharma ASA


As the leader in Vitamin K2 research & development, NattoPharma has not only created the Vitamin K2 category, but continues to drive it forward. Offering the best and first clinically validated and patented Vitamin K2 as MK-7 on the market, MenaQ7®, NattoPharma has sponsored the groundbreaking research that has confirmed K2’s essential role in bone and cardiovascular health, for old and young alike.

NattoPharma’s mission is to advance global health by creating and introducing to the market scientifically validated products and technologies that will deliver measurable health benefits and optimal health outcomes.

This mission is accomplished by:

• Addressing significant health concerns with branded, scientifically validated, proprietary products and technologies, leading with our flagship brand MenaQ7®;

• Leveraging all manner of technology to more effectively and efficiently deliver these products to our target markets;

• Solidifying ourselves as the experts in the science underlying our products and associated enabling technologies that allow us to effectively deliver them to the marketplace; and

• Developing and maintaining a deep customer and segment understanding of the benefits we deliver.

With 19+ published studies and even more underway, NattoPharma has an unparalleled patent portfolio related to relevant health benefits and market segments, creating extra values for its customers.  

MenaQ7® meets the growing demand for highly pure, stable K2 for supplemental and food use in any different format.

The most comprehensive Vitamin K2 ingredient portfolio meeting market needs:

MenaQ7® Natural MK-7: 96% pure all-trans MK-7 free of soy and other allergens.

MenaQ7® PharmaPure MK-7: The only all-trans nature-identical synthetic, winner of 2015   NutrAward for Best Functional Ingredient

MenaQ7® Natto MK-7: 96% active all-trans soy fermented MK-7

MenaQ7® Full Spectrum K2: The first and only K2 to deliver menaquinone isomers MK-6, 7, 8, and 9, free from soy and other allergens.

All material is available with CryoCap microencapsulation, ensuring stable menaquinone protection in any formulation.

The MenaQ7® brand is built upon 6 Pillars of Excellence, a platform delivering the most safe and efficacious Vitamin K2 on the market, creating opportunities for manufacturers and value for end users:

• Trusted Expertise

• Science Leader

• Superior Products

• Continuous Innovation

• Educational Marketing

• Cooperative Support

Visit website for more information: www.menaq7.com 

Related Articles

Health & Nutrition News

Weekly Roundup: BioCell Collagen featured in Joint Support launch, Nutritional benefits of grass-fed dairy highlighted

26 Oct 2018 --- This week in nutrition, BioCell Collagen is featured in a product launch by Bluebonnet Targeted Choice, coined Joint Support. Rupa Das, BI’s Vice President of Global Quality and Compliance, was appointed as the interim chair for the American Herbal Products Association Board of Trustees. A Teagasc organized “Grass-Fed Dairy Conference” highlighted the benefits of grass-fed dairy systems on the nutritional composition of dairy products and a NattoPharma ASA sponsored symposium in the Netherlands examined the impact of vitamin K2 on arteries and bones.

Health & Nutrition News

Key nutritional drivers: Growing consumer knowledge, holistic health and the mainstreaming of supplementation

10 Jul 2018 --- The future platforms for innovation in nutritionals are being shaped by a range of consumer drivers, including an increasing interest in holistic approaches to health, a growing knowledge of nutrition and the mainstreaming of supplements. NutritionInsight speaks with an array of suppliers on these consumer interests so keenly driving trends.

Health & Nutrition News

Weekly Digest: NP Nutra triples its warehouse space, broccoli named US top vegetable

15 Jun 2018 --- This week in nutrition, research studies affirmed the benefit of vitamin K2 for healthy bones, vitamin E tocotrienol may delay paralysis associated with Alzheimers and vegetables took center stage in the US with a survey identifying broccoli as the nations favorite and large investments were made in school plant-based cafeteria options. At a sports nutrition conference, Nitrosamines positive effects on cognitive function were announced, while National Institutes of Health launched a new app aimed at providing safe information on popular herbs. Concerning expansions, NP Nutra expanded its warehouse in California and Azelis opened a new pharmaceutical manufacturing facility in Germany.

Health & Nutrition News

Weekly Digest: Plant-based diet boosts healthy hearts, GMP registration for OmniActive health ingredients plant

08 Jun 2018 --- This week in nutrition, OmniActive has had its Hosur plant, that manufactures natural extracts, gain Good Manufacturing Practice (GMP) from NSF and Omya International had its orally disintegrating tablets confirmed by a scientific study. The benefits of a plant-based diet for a healthy heart were touted by researchers, including lower cholesterol and blood pressure. Lastly, NattoPharma and its pharmaceutical spin-off Kaydence Pharma appointed new CEO's amid positive growth results and Lycored appoints a new SVP as it seeks to grow R&D capabilities.

Health & Nutrition News

NattoPharma spearheads vitamin K2 RDI program

04 Jun 2018 --- Norway-based biotech company NattoPharma has enlisted its research partners to start a program to establish what the company says is a much-needed Recommended Daily Intake (RDI) for vitamin K2. 

More Articles
URL : http://www.nutritioninsight.com:80/news/hearty-results-menaq7-k2-study-confirms-vascular-health-benefits-for-men-and-women.html